These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38170484)

  • 1. Cost analysis of self-monitoring blood glucose in nonintensively managed type 2 diabetes.
    Kerr D; Duncan I; Repetto E; Maroun R; Wu A; Perkins C; Bergman G; Giorgino F
    Am J Manag Care; 2023 Dec; 29(12):670-675. PubMed ID: 38170484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes.
    Yeaw J; Lee WC; Aagren M; Christensen T
    J Manag Care Pharm; 2012; 18(1):21-32. PubMed ID: 22235952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in Diabetes-Related Hospitalizations and Medical Costs After Dexcom G6 Continuous Glucose Monitor Initiation in People with Type 2 Diabetes Using Intensive Insulin Therapy.
    Hannah KL; Nemlekar PM; Green CR; Norman GJ
    Adv Ther; 2024 Jun; 41(6):2299-2306. PubMed ID: 38619722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous glucose monitoring systems for type 1 diabetes mellitus.
    Langendam M; Luijf YM; Hooft L; Devries JH; Mudde AH; Scholten RJ
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD008101. PubMed ID: 22258980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Interventional Evidence.
    Seidu S; Kunutsor SK; Ajjan RA; Choudhary P
    Diabetes Care; 2024 Jan; 47(1):169-179. PubMed ID: 38117991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France.
    Alshannaq H; Pollock RF; Joubert M; Ahmed W; Norman GJ; Lynch PM; Roze S
    J Comp Eff Res; 2024 Mar; 13(3):e230174. PubMed ID: 38294332
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Effectiveness of Continuous Glucose Monitoring in Pregnancies Affected by Type 1 Diabetes.
    Gao V; Snell-Bergeon JK; Malecha E; Johnson CA; Polsky S
    Diabetes Technol Ther; 2024 Aug; 26(8):526-535. PubMed ID: 38386433
    [No Abstract]   [Full Text] [Related]  

  • 8. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.
    Karter AJ; Parker MM; Moffet HH; Gilliam LK; Dlott R
    JAMA; 2021 Jun; 325(22):2273-2284. PubMed ID: 34077502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.
    Riemsma R; Corro Ramos I; Birnie R; Büyükkaramikli N; Armstrong N; Ryder S; Duffy S; Worthy G; Al M; Severens J; Kleijnen J
    Health Technol Assess; 2016 Feb; 20(17):v-xxxi, 1-251. PubMed ID: 26933827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump.
    Rubin RR; Peyrot M
    J Diabetes Sci Technol; 2009 Nov; 3(6):1402-10. PubMed ID: 20144395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Effects of Continuous Glucose Monitoring on Physical Activity Habits and Blood Lipid Levels in Persons With Type 1 Diabetes Managed With Multiple Daily Insulin Injections: An Analysis Based on the GOLD Randomized Trial (GOLD 8).
    Nyström T; Schwarz E; Dahlqvist S; Wijkman M; Ekelund M; Holmer H; Bolinder J; Hellman J; Imberg H; Hirsch IB; Lind M
    J Diabetes Sci Technol; 2024 Jan; 18(1):89-98. PubMed ID: 35677967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective.
    Chaugule S; Graham C
    J Med Econ; 2017 Nov; 20(11):1128-1135. PubMed ID: 28745578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada.
    Alshannaq H; Isitt JJ; Pollock RF; Norman GJ; Cogswell G; Lynch PM; Roze S
    J Comp Eff Res; 2023 Oct; 12(10):e230075. PubMed ID: 37668608
    [No Abstract]   [Full Text] [Related]  

  • 16. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial.
    van Beers CA; DeVries JH; Kleijer SJ; Smits MM; Geelhoed-Duijvestijn PH; Kramer MH; Diamant M; Snoek FJ; Serné EH
    Lancet Diabetes Endocrinol; 2016 Nov; 4(11):893-902. PubMed ID: 27641781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flash CGM associated with event reduction in nonintensive diabetes therapy.
    Miller E; Kerr MSD; Roberts GJ; Nabutovsky Y; Wright E
    Am J Manag Care; 2021 Nov; 27(11):e372-e377. PubMed ID: 34784145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost implications of continuous glucose monitoring in pregnant women with type 1 diabetes in 3 Canadian provinces: a posthoc cost analysis of the CONCEPTT trial.
    Ahmed RJ; Gafni A; Hutton EK; Hu ZJ; Sanchez JJ; Murphy HR; Feig DS;
    CMAJ Open; 2021; 9(2):E627-E634. PubMed ID: 34088734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittently scanned continuous glucose monitoring provides no benefit over structured self-monitoring of blood glucose in type 2 diabetes not on prandial insulin, in the context of diabetes self-management education: GLucose monitoring programme SingaporE (GLiMPSE).
    Rama Chandran S; Rahman N; Gandhi M; Tan NC; Phoon IKY; Seah DEJ; Cheah MH; Sek K; Gardner DS
    Diabetes Res Clin Pract; 2024 May; 211():111678. PubMed ID: 38642860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous glucose monitoring for patients with diabetes: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2011; 11(4):1-29. PubMed ID: 23074416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.